Holen Sie sich die Stockscreener-App
0.75
0.31%
-0.0023
Handel nachbörslich:
.75
Schlusskurs vom Vortag:
$0.7523
Offen:
$0.752
24-Stunden-Volumen:
15,749
Relative Volume:
0.31
Marktkapitalisierung:
$29.10M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-24.77M
KGV:
-0.974
EPS:
-0.77
Netto-Cashflow:
$-17.36M
1W Leistung:
+0.25%
1M Leistung:
-7.41%
6M Leistung:
-17.43%
1J Leistung:
-31.82%
1-Tages-Spanne:
$0.735
$0.752
1-Wochen-Bereich:
$0.735
$0.77
52-Wochen-Spanne:
$0.711
$1.90
Mink Therapeutics Inc Stock (INKT) Company Profile
Firmenname
Mink Therapeutics Inc
Sektor
Branche
Telefon
212-994-8250
Adresse
149 FIFTH AVENUE, NEW YORK
Mink Therapeutics Inc Aktie (INKT) Neueste Nachrichten
Twin Lakes Capital Management LLC Sells 125 Shares of The Boeing Company (NYSE:BA) - Defense World
Jarvis Securities (LON:JIM) Reaches New 1-Year Low at $43.00 - Defense World
ProShare Advisors LLC Sells 3,900 Shares of Plains All American Pipeline, L.P. (NYSE:PAA) - Defense World
103,800 Shares in E2open Parent Holdings, Inc. (NYSE:ETWO) Bought by Ensign Peak Advisors Inc - Defense World
AFC Energy plc (OTCMKTS:AFGYF) Short Interest Up 5.2% in September - Defense World
CAE Inc. (NYSE:CAE) Shares Purchased by Brandes Investment Partners LP - Defense World
QXO, Inc. (NASDAQ:QXO) Short Interest Update - Defense World
CAR-T Cell Therapy Clinical Trials 2024: FDA Approvals, - openPR
Mink Therapeutics stock hits 52-week low at $0.74 amid market challenges - Investing.com
Mink Therapeutics stock hits 52-week low at $0.74 amid market challenges - Investing.com Canada
Mink Therapeutics stock hits 52-week low at $0.74 amid market challenges - Investing.com Australia
Mink Therapeutics stock hits 52-week low at $0.74 amid market challenges - Investing.com UK
MiNK Therapeutics faces potential Nasdaq delisting - Investing.com
Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024 - Business Wire
Mink Ventures Reports Positive Base Metal Assays From Sampling Program at Warren Copper Nickel Cobalt Project, Timmins, Ontario - Yahoo Finance
MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference - GlobeNewswire
Agenus to Participate in September Investor Conferences - Business Wire
MiNK Therapeutics, Inc. (NASDAQ:INKT) Short Interest Update - Defense World
MiNK Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com South Africa
MiNK Therapeutics faces Nasdaq delisting over share price - Investing.com India
MiNK Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com UK
MiNK Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Canada
SEC Form 424B3 filed by MiNK Therapeutics Inc. - Quantisnow
Needham & Company LLC Boosts Globant (NYSE:GLOB) Price Target to $245.00 - Defense World
Lazard, Inc. to Post Q3 2024 Earnings of $0.49 Per Share, Zacks Research Forecasts (NYSE:LAZ) - Defense World
HC Wainwright Equities Analysts Boost Earnings Estimates for MiNK Therapeutics, Inc. (NASDAQ:INKT) - Defense World
Q3 2024 Earnings Forecast for Jushi Holdings Inc. Issued By Seaport Res Ptn (OTCMKTS:JUSHF) - Defense World
Head-To-Head Analysis: Postal Realty Trust (NYSE:PSTL) and Starwood Property Trust (NYSE:STWD) - Defense World
CureVac (NASDAQ:CVAC) Price Target Cut to $16.00 by Analysts at JMP Securities - Defense World
CEMIG (NYSE:CIG) Reaches New 1-Year High at $2.13 - Defense World
Royal Bank of Canada Reiterates Outperform Rating for Privia Health Group (NASDAQ:PRVA) - Defense World
HC Wainwright Comments on Jasper Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:JSPR) - Defense World
Q3 2024 EPS Estimates for Iridium Communications Inc. (NASDAQ:IRDM) Boosted by Zacks Research - Defense World
MiNK Therapeutics (NASDAQ:INKT) Stock Rating Reaffirmed by HC Wainwright - Defense World
HLS Therapeutics Inc. (TSE:HLS) to Post Q3 2024 Earnings of ($0.19) Per Share, Stifel Canada Forecasts - Defense World
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q2 2024 Earnings Call Transcript - Insider Monkey
Earnings call: MiNK Therapeutics reports Q2 2024 progress By Investing.com - Investing.com South Africa
Earnings call: MiNK Therapeutics reports Q2 2024 progress By Investing.com - Investing.com Canada
Earnings call: MiNK Therapeutics reports Q2 2024 progress - Investing.com
Earnings call: MiNK Therapeutics reports Q2 2024 progress - Investing.com India
INKT Stock Earnings: MiNK Therapeutics Beats EPS for Q2 2024 - InvestorPlace
MiNK Reports Second Quarter 2024 Results and Business Update - GlobeNewswire
MiNK Reports Second Quarter 2024 Results and Business Update - Yahoo Finance
Acute Respiratory Distress Syndrome Pipeline 2024 | Staidson (Beijing) Biopharmaceuticals Co., Ltd, Cartesian Therapeutics, GEn1E Lifesciences, Aqualung Therapeutics Corp., Theratome Bio - Barchart
MiNK Therapeutics (INKT) Scheduled to Post Quarterly Earnings on Tuesday - Defense World
Agenus Inc (AGEN) Q2 2024 Earnings: EPS of -$2.52 Beats Estimates, Revenue of $23.5M Misses Expectations - GuruFocus.com
CAR-T Cell Therapy Clinical Trials Analysis 2024: FDA - openPR
MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report - StockTitan
MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report - Yahoo Finance
MiNK Therapeutics meets Nasdaq capital requirement - Investing.com India
MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement - GlobeNewswire
Finanzdaten der Mink Therapeutics Inc-Aktie (INKT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
4.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):